Mike Carrel

“Atric Care delivered another strong quarter, generating worldwide revenue of $154.5 million, an increase of 15% year-over-year.”

“And we're now about, this year we'll do over $600 million in revenue. The position right now, though, is that we've got a vision 2030 to do a billion dollars in revenue by the end of this decade.”

“I talked about number one is the LEAPS trial, which is a trial we started well before we knew this competition was coming into the space, is that upon, like, we invested in it, we're fully enrolled in it, we will be the only company with a stroke label that is very specific to our product.”

“I am delighted to announce another strong quarter for AtriCure, once again demonstrating the broad-based activity in our business and global revenue drivers. In the third quarter, we achieved total revenue of $98 million, representing 18% year-over-year growth.”

“I am very proud to report another outstanding quarter at AtriCure as our team continues to expand patient care and awareness for the treatment of Afib, left atrial appendage management, and postoperative pain management.”